BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28012969)

  • 1. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients.
    Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
    Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
    Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
    Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
    BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma.
    DiNatale RG; Sanchez A; Hakimi AA; Reznik E
    Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
    Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
    Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Genes Involved in Cellular Adhesion and Extracellular Matrix Remodeling Correlates with Poor Survival of Patients with Renal Cancer.
    Boguslawska J; Kedzierska H; Poplawski P; Rybicka B; Tanski Z; Piekielko-Witkowska A
    J Urol; 2016 Jun; 195(6):1892-902. PubMed ID: 26631499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic profiling reveals key metabolic features of renal cell carcinoma.
    Catchpole G; Platzer A; Weikert C; Kempkensteffen C; Johannsen M; Krause H; Jung K; Miller K; Willmitzer L; Selbig J; Weikert S
    J Cell Mol Med; 2011 Jan; 15(1):109-18. PubMed ID: 19845817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microarray gene expression profiling and analysis in renal cell carcinoma.
    Liou LS; Shi T; Duan ZH; Sadhukhan P; Der SD; Novick AA; Hissong J; Skacel M; Almasan A; DiDonato JA
    BMC Urol; 2004 Jun; 4():9. PubMed ID: 15212686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems.
    Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M
    Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
    Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
    Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.
    Hakimi AA; Reznik E; Lee CH; Creighton CJ; Brannon AR; Luna A; Aksoy BA; Liu EM; Shen R; Lee W; Chen Y; Stirdivant SM; Russo P; Chen YB; Tickoo SK; Reuter VE; Cheng EH; Sander C; Hsieh JJ
    Cancer Cell; 2016 Jan; 29(1):104-116. PubMed ID: 26766592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathway analysis of kidney cancer using proteomics and metabolic profiling.
    Perroud B; Lee J; Valkova N; Dhirapong A; Lin PY; Fiehn O; Kültz D; Weiss RH
    Mol Cancer; 2006 Nov; 5():64. PubMed ID: 17123452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia.
    Karim S; Al-Maghrabi JA; Farsi HM; Al-Sayyad AJ; Schulten HJ; Buhmeida A; Mirza Z; Al-Boogmi AA; Ashgan FT; Shabaad MM; NourEldin HF; Al-Ghamdi KB; Abuzenadah A; Chaudhary AG; Al-Qahtani MH
    BMC Cancer; 2016 Sep; 16(Suppl 2):741. PubMed ID: 27766950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
    Mitsui Y; Hirata H; Arichi N; Hiraki M; Yasumoto H; Chang I; Fukuhara S; Yamamura S; Shahryari V; Deng G; Saini S; Majid S; Dahiya R; Tanaka Y; Shiina H
    Oncotarget; 2015 Apr; 6(11):9577-91. PubMed ID: 25797254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma.
    Lucarelli G; Rutigliano M; Sallustio F; Ribatti D; Giglio A; Lepore Signorile M; Grossi V; Sanese P; Napoli A; Maiorano E; Bianchi C; Perego RA; Ferro M; Ranieri E; Serino G; Bell LN; Ditonno P; Simone C; Battaglia M
    Aging (Albany NY); 2018 Dec; 10(12):3957-3985. PubMed ID: 30538212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in levels of metabolic pathway gene expression under conditions of clear cell renal carcinoma.
    Bashmakov VY; Gorbacheva TM; Panevina AV; Solodskikh SA; Moshurov IP; Mikhaylov AA; Maslov AY; Popov VN
    Dokl Biochem Biophys; 2017 May; 474(1):159-161. PubMed ID: 28726105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network-based metabolic characterization of renal cell carcinoma.
    Pandey N; Lanke V; Vinod PK
    Sci Rep; 2020 Apr; 10(1):5955. PubMed ID: 32249812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
    Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
    BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations.
    Bilim V; Kawasaki T; Katagiri A; Wakatsuki S; Takahashi K; Tomita Y
    Clin Cancer Res; 2000 Feb; 6(2):460-6. PubMed ID: 10690524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Transcriptome profiling of formalin-fixed, paraffin-embedded renal cell carcinoma by RNA-seq.
    Li P; Conley A; Zhang H; Kim HL
    BMC Genomics; 2014 Dec; 15(1):1087. PubMed ID: 25495041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.